Rifaquizinone
Pharmaceutical compound From Wikipedia, the free encyclopedia
Rifaquizinone (RFQ, CBR-2092, TNP-2092) is an experimental antibiotic medication developed in China for the treatment of bacterial infections such as drug-resistant strains of Staphylococcus aureus. It is an orally active prodrug which is also a codrug, being cleaved inside the body to two active components, with half of the molecule being a rifamycin derivative, and the other half a quinolone antibiotic. It is in clinical trials for joint infections following surgery and acute bacterial skin and skin structure infections.[1][2][3][4]
![]() | |
Clinical data | |
---|---|
Other names | RFQ, CBR-2092, TNP-2092 |
Routes of administration | Oral, intravenous |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C65H81FN6O15 |
Molar mass | 1205.388 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.